Resources from the same session
1O - KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
Presenter: Rebecca Dent
Session: Proffered paper session on Breast cancer
Resources:
Abstract
Slides
Webcast
43O - Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia
Presenter: Mastura Md Yusof
Session: Proffered paper session on Breast cancer
Resources:
Abstract
Slides
Webcast
44O - Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation
Presenter: Seock-Ah Im
Session: Proffered paper session on Breast cancer
Resources:
Abstract
Slides
Webcast
45O - Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2
Presenter: Chiun-Sheng Huang
Session: Proffered paper session on Breast cancer
Resources:
Abstract
Slides
Webcast
46O - Neratinib + capecitabine (N+C) vs lapatinib + capecitabine (L+C) in Asians with HER2+ metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial
Presenter: Ming Shen Dai
Session: Proffered paper session on Breast cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 45O and 46O
Presenter: Prudence Francis
Session: Proffered paper session on Breast cancer
Resources:
Slides
Webcast
LIVE Q&A
Presenter: Sung-Bae Kim
Session: Proffered paper session on Breast cancer
Resources:
Webcast
LIVE Q&A
Presenter: Sung-Bae Kim
Session: Proffered paper session on Breast cancer
Resources:
Webcast